There is a moment, familiar to every generic drug executive, when a promising target drug goes from ‘opportunity’ to ‘nightmare.’ […]

The call came on a Tuesday morning. A general counsel at a mid-sized specialty pharma company had just received a

By the time a generic development team discovers that a drug’s composition-of-matter patent expires in three years, the real work

Every patent a pharmaceutical company files is a sworn, detailed confession. It tells you what the company’s chemists have been

Who this is for: Formulation scientists, regulatory affairs directors, IP counsel, and business development executives at generic and specialty pharmaceutical

Every year, somewhere between $20 billion and $80 billion in branded drug revenue falls off a cliff. Not metaphorically. Literally:

In the summer of 2022, a mid-sized generic manufacturer’s legal team spent six weeks and roughly $400,000 running keyword searches

Every formulation patent is a public confession. The inventor must disclose, in precise technical detail, exactly what makes the product

Biologic drugs account for roughly 2% of all U.S. prescriptions. They generate 37% of total net drug spending [1]. That